Correspondence 0001104659-23-111290 from Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc
Date: Oct. 25, 2023 · CIK: 0001541157 · Accession: 0001104659-23-111290
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275119
Letter
Securities and Exchange Commission Division of Corporation Finance Re: Akari Therapeutics, Plc (the “Company”) Registration Statement on Form F-3 (the “Registration Statement”) Filed October 20, 2023 File No. 333-275119
Dear Mr. Drory:
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 4:00 p.m. Eastern Time on October 26, 2023, or as soon thereafter as practicable.
[Signature Page Follows]
Very truly yours,
AKARI THERAPEUTICS, PLC
Show Raw Text
CORRESP
1
filename1.htm
Akari Therapeutics, Plc
22 Boston Wharf Road FL 7
Boston, MA 02210
October 25, 2023
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Akari Therapeutics, Plc (the “Company”)
Registration Statement on Form F-3 (the “Registration Statement”)
Filed October 20, 2023
File No. 333-275119
Dear Mr. Drory:
The Company hereby requests,
pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement
so that such Registration Statement will become effective as of 4:00 p.m. Eastern Time on October 26, 2023, or as soon thereafter as practicable.
[Signature Page Follows]
Very truly yours,
AKARI THERAPEUTICS, PLC
By:
/s/ Rachelle Jacques
Name:
Rachelle Jacques
Title:
President and Chief Executive Officer